Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, using Persist's AI-based formulation technology and Nivagen's manufacturing capabilities. The collaboration aims to simplify and accelerate the development and approval of LAI drugs, which can provide sustained and controlled release of...
Scispot, a leading provider of modern lab tech stack solutions, is thrilled to announce its new purpose-built Pathology LIMS alternative, engineered to deliver lightning-fast performance from sample intake to processing, instrument data analysis, and reporting. This new GenAI-powered solution is designed to help pathology labs process samples 5-10x faster,...
eLabNext, an Eppendorf Group Company offering a flexible Digital Laboratory Platform equipped with a Laboratory Inventory Management System (LIMS) and Electronic Lab Notebook (ELN), announced that they’ve entered into a “preferred vendor” partnership with US Lab Partners, a strategic consulting and advisory firm that provides life sciences companies with...
BIOMAKERS, a Precision Medicine & Biotech Company that supports data-driven Drug Development globally, and TOPAZIUM, an AI-driven healthtech company specializing in drug discovery and human wellbeing, have announced the results of their innovative collaborative project. This partnership showcases the power of AI systems in leveraging real-world DNA sequencing data to...
Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable biomarkers, and who should receive confirmatory testing in accordance with clinical guidelines. This program...
EVERSANA, a leading provider of global commercial services to the life sciences industry, introduced TEDAVI, the pharmaceutical and life science industry’s premier content transformation hub built to streamline content production, enable personalization at scale and accelerate time-to-market for brand assets while ensuring compliance.
Developed by the company’s world-class global agency...
Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools
Rejuvenate Biomed and SAS announced a partnership to develop a user-friendly drug repurposing discovery tool for researchers and scientists to uncover medically relevant insights about drugs, diseases, and biological networks, through fast and...
Mr Tulk will spearhead innovative digital solutions, advanced analytics, and new offerings for Vaniam Group's clients.
As the biopharmaceutical industry continues to evolve with the rapid integration of advanced technologies, Vaniam Group™ is poised to lead this transformation with the appointment of Steve Tulk as the agency's first Chief Technology Officer (CTO). This strategic...
Enhancements in key models power HT-PBPK simulations and AI-driven drug design with unprecedented performance and accuracy
Simulations Plus, Inc, a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, announced the release of version 12.0 of ADMET Predictor® (AP12), its flagship machine learning (ML)...
Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease. The collaboration between Remix and Tempus began with the licensing of specific, de-identified...
